TY - JOUR T1 - Managing hypertriglyceridemia in children with systemic lupus erythematosus: Two sides of the same coin JO - Reumatología Clínica T2 - AU - Basu,Biswanath AU - Babu,Binu George AU - Bhattacharyya,Suman SN - 1699258X M3 - 10.1016/j.reuma.2016.09.003 DO - 10.1016/j.reuma.2016.09.003 UR - https://reumatologiaclinica.org/es-managing-hypertriglyceridemia-in-children-with-articulo-S1699258X16301085 AB - Hypertriglyceridemia is common in children with systemic lupus erythematosus (SLE). A retrospective analysis of the baseline clinical–pathological presentation and treatment outcome (status of lipid profiles) was performed in two children with SLE, who presented with extreme hypertriglyceridemia over a follow-up period of four weeks. The children were treated with prednisolone, mycophenolate mofetil (MMF), hydroxychloroquine and hypolipidemic agents, depending on their disease status. On serial follow-up, the first child showed a significantly raised serum triglyceride level after receiving one week of oral prednisolone therapy. Anti-lipoprotein-lipase (LPL) autoantibody was absent. Lipid profile levels of this child gradually improved after replacing oral prednisolone with another immunosuppressant, namely MMF. The second child presented with extreme hypertriglyceridemia with positive anti-LPL autoantibody. She responded to plasmapheresis followed by increasing the dose of immunosuppressant. So, extreme hypertriglyceridemia in children with SLE may be steroid induced or due to presence of anti-LPL auto antibody. Management should be individualized depending on the etiology. ER -